Tarlock K, Lamble AJ, Wang Y-C, et al. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children’s Oncology Group. Blood. 2021;138(13):1137-1147.

In Figure 5 on page 1145, the numbers of patients in the CEBPA⁺/GATA2⁺ and CEBPA⁺/CSF3R⁺ molecular cohorts are reversed. In Figure 5A and C, the curves should be labeled as 23 patients with CEBPA⁺/GATA2⁺ and 13 patients with CEBPA⁺/CSF3R⁺. In Figure 5B, the curves should be labeled as 20 patients with CEBPA⁺/GATA2⁺ and 13 patients with CEBPA⁺/CSF3R⁺. The correct numbers of patients were used for analysis. The corrected Figure 5 is shown below.

Figure 5.

Outcomes of CEBPA-mutant patients according to co-occurring CSF3R and GATA2 mutational status. (A) EFS of dual CEBPA⁺/CSF3R⁺ mutant patients compared with those with dual CEBPA⁺/GATA2⁺ and those with a CEBPA⁺ mutation and neither CSF3R nor GATA2; (B) RR of dual CEBPA⁺/CSF3R⁺ mutant patients compared with dual CEBPA⁺/GATA2⁺ and patients with a CEBPA⁺ mutation and neither CSF3R nor GATA2; (C) OS of dual CEBPA⁺/CSF3R⁺ mutant patients compared with dual CEBPA⁺/GATA2⁺ and patients with a CEBPA⁺ mutation and neither CSF3R nor GATA2.

The errors have been corrected in the online version of the article.